CA1211713A - Paste for haemostasis and temporary bridging of defects in cases of bone trauma - Google Patents
Paste for haemostasis and temporary bridging of defects in cases of bone traumaInfo
- Publication number
- CA1211713A CA1211713A CA000446593A CA446593A CA1211713A CA 1211713 A CA1211713 A CA 1211713A CA 000446593 A CA000446593 A CA 000446593A CA 446593 A CA446593 A CA 446593A CA 1211713 A CA1211713 A CA 1211713A
- Authority
- CA
- Canada
- Prior art keywords
- paste
- bone
- defects
- haemostasis
- cases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Composite Materials (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Materials Engineering (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
- Dental Preparations (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Noodles (AREA)
Abstract
Abstract of the Disclosure A paste for haemostasis in cases of bone trauma, containing a prolamin, such as zein and tricalcium phosphate or hydroxyl apatite in finely dispersed form and a physiologically compatible diluent, such as aqueous ethanol. The paste is applied on the traumatized bone. The paste also may serve for temporary bridg-ing of defects in bones.
Description
L2~ 3 The invention relates to a paste for haemostasis and temporary bridging of defects in cases of bone trauma.
Since 1892 the bone wax first described by Horsley and later on modified in various ways has been used as a means of mechanically stopping the bleeding of bones. Its original composition was 7 parts of bees wax, 1 part of almond oil, and 1 part of almond oil, and 1 part of salicyclic acid. The bone wax most frequently used today consists of 89 parts of bees wax and 11 parts of isopropyl palmitate. This preparation causes strong foreign-substance reactions and chronic inflammation reactions. A minor portion only is re-sorbed within 12 weeks, while at the same time the osteo-anagenesis is delayed considerably. From the clinical point of view, the possible formation of pseudo arthroses must be watched.
.
It is the ob~ect of the invention to provide a paste for haemostasis and temporary bridging of defects in cases of bone trauma, which paste will safely stop bleeding of the traumatized bone and not impede the osteogenesis but rather act osteoinductively. The solution of the problem posed is on the surprising finding that a paste containing 8 prolamin and finely dis-persed tricalcium phosphate or hydroxyl apatite and a physiologically com-patible diluent provides optimum haemostasis of the traumatized bone and is an excellent means for the temporary bridging of defects.
In accordance with the present teachings, a paste is provided for haemo-stasis and temporary bridging of defects in cases of bone trauma character-ized in that it contains from 3 to 60% by weight of prolamin and from 5 to 20% of tricalcium phosphate or hydroxyl apatite in finely dispersed form and a physiologically compatible diluent.
The diluent used preferably is a mixture of an aliphatic alcohol having from 2 to 5 carbon atoms, particularly ethanol and water at a volumetric ratio of approximately 1:1 to 10:0.5.
Prolamins are the major protein constituents of cereal grains or meal.
Contrary to all other proteins they can be extracted from flour by the use of 80% alcohol, yet they are not soluble in anhydrous alcohol or water. The most important prolamins are zein, gliadin, and hordein.
Zein is preferred in accordance with the invention. The prolamin, preferably zein is used in ,_~
23L~713 the paste in a quantity of from about 3 to 60, preferably 5 to 45% by weight.
Contrary to all other proteins, the prolamins are soluble in diluted alcohols and other solvents, but are not soluble in water. A mixture of ethanol and water is the preferred solvent and diluent, the water content ranging between 4 and 50%, depend-ing on how quickly the prolamin is desired to precipitate. In ethanol prolamins yield viscous, slightly thixotropic solutions.
The viscosity of the solutions rises as the concentration of ethanol rises, at the same prolamin content. On the other hand, the viscosity increases as the concPntration of prolamin in-creases, at a given concentration of ethanol.
The prolamins are resorbable so pseudoarthrosis cannot develop which is conceivable as a consequence of bone wax not being re-sorbed or being resorbed too slowly, e.g. in case of sternum closure.
The contents of finely dispersed hydroxyl apatite or tricalcium phosphate promote the regeneration of the bone. The particle size of the hydroxyl apatite or tricalcium phosphate in general lies within a range of from approximately 3 to 20 ~m, particu-larly from approximately 10 to 15 ~m.
The addition of methyl cellulose or carboxymethyl cell~lose in an amount of from 2 to 10% by weight provides optimum consisten-cy of the paste, thus yielding a preparation to stop bleeding of the bone when applied easily as a thin film. Also greater bone defects ca~ be filled and bridged by applying the paste.
Furthermore, it is possible to repair comminuted fractures.
An antibiotic may be added to the paste for use in prophylaxis and therapy of infections. Specific examples of useful anti-biotics are tobramycin, gentamycin, cefotaxim, and mixtures thereof. The antibiotic is used in suffici~ntly great quantity to obtain the complete inhibition of growth of the germs to be killed.
Instead of or in addition to the antibiotic the paste may con-tain a cytostatic drug. Specific examples of cytostatic sub-stances are mitomycin, dichlorene, decarbacin, or cisplatin.
~2~ 3 The cytostatic drug is used in an amount sufficient to retard the growth of the tumor.
Upon addition of fine fibers of resorbable polymer in an amount of from 1 to 15% by weight the consistency is changed such that the mass becomes kneadable and moldable so that it may be applied as a temporary bridging means of defects on bones~
Poly-~lactide-co-glycolide) is an hydrolyzable aliphatic poly-ester used to produce resorbable surgical suture material. Other resorbable fibrous polymers which may be incorporated in the paste according to the invention are polyglycolide, polylactide, polyoxalate, polysuccinate, polydioxanone, and poly-(esteramides).
The paste may be prepared in a way as disclosed in US patent 4,268,495 from which injectable solutions containing prolamin are known for embolization and occlusion.
It is easy to press the kneadable paste into bone defects and mold it so as to adapt it to the desired shape The mass solidi-fies within a period of from about 30 to 90 minutes.
The paste may be sterilized by gamma radiation, heat, or the addition of propylene oxide in an amount of from about 0.25 to 0.5% by weight.
The examples will explain the invention.
Example 1 A paste is prepared from the following components:
ethanol 60% V/V 51.7 g zein 19.4 g methyl cellulose 5.0 g tricalcium phosphate (particle size about 10~m~ 15.0 g propylene oxide 1.0 g The zein is introduced into the 60% aqueous ethanol, while care-fully stirring the mass. Upon complete dissolution (about 12 to 14 hours) pH adjustment is made to approximately 6.5 to 6.8, with the aid of a physiologically compatible acid or base . The ethyl cellulose and tricalcium phosphate then are introduced into the viscous solution obtained. The resulting paste finally is mixed in the cold with 1 g of propylene oxide and immediately bottled. An additional 1 to 13 g of fine fibers of a resorbable polymer, preferably polyglycolide or polylactide may be incorporated in the paste.
Example 2 In accordance with example 1 a paste is prepared from the com-ponents below:
ethanol 60% V~V 51.7 g zein 19.4 g carboxymethyl cellulose - 5.0 g hydroxyl apatite (particle size about 10 ~m) 20.0 g propylene oxide 1.0 g Upon longitudinal separation of the sternum of a dop the paste prepared in accordance with examples 1 and 2 is applied on the spongy part of the bone to stop the bleeding. The paste is applicable well and smoothly penetrates into the tiny cavities of the bone. Diffuse bleeding out of the bone is stopped at once.
Upon obduction after 28 days the partial bridging of the former defect can be observed. Histological proof of the haemostatic substance is no longer possible.
Example 3 In accordance with example l a paste is prepared from the components listed below:
ethanol 60% V/V 51.7 g zein 19.4 g methyl cellulose 5.0 g tricalcium phosphate (particle size about 10 ~m) 15.0 g tobramycin 0.7 g propylene oxide 1.0 g The paste according to the invention is used to fill an infect-ed bone cavity. Bone cavities in the ehronically infected bone marrow are a locus minoris resistentiae for recurring infections.
12~7~3 Upon cleaning of the bone marrow space up to sound tissue the paste is used to stop the bleeding which begins. At the same time the cavity either is filled completely or lined along the walls, depending on ~he size. The precipitation which initiates at once stops the paste from flowing out.
In a bacteriological test the bone pieces withdrawn periodically in the experiment demonstrated distinct inhibition of germ growth heyond the 28th day, and then at a declining tendency.
Example 4 In accordance with example 1 a paste is prepared from the fol-lowing components:
ethanol 60~ V/V 51.7 g zein 19O4 g carboxymethyl cellulose 5.0 g hydroxyl apatite (particle size about 10 ~m) 20.0 g mitomycin 0.8 g propylene oxide 1.0 g The paste according to the invention is used to retard the growth of malignant tumoxs of the bone or bone marrow which certainly or perhaps are existing. In context with the cytostatic drug mitomycin the paste either may be applied in a flowable consi-stency or in the form of the finest solid particles upon preci-pitation or evaporation of the solvent.
The flowable form wil~ be chosen if it is desired that the paste stop heavy bleeding from the area of tumor. Again a bone tumor may be treated which either is known and considered inoperable or which has been operated on and requires measures to stop the bleeding. The prophylactic introduction of a cytostatic drug to the border of the excision is of great advantage because in this way it can be guaranteed that the effectiveness of the cy-tostatic substance will last long enough. The range of the ef-fectiveness is to be assumed to reach about 1 cm away from the paste. As a systemic effect here is given under certain condi-tions only, the release of the cytostatic drug may be very high.
In fact it still amounts to several gamma up to a distance of
Since 1892 the bone wax first described by Horsley and later on modified in various ways has been used as a means of mechanically stopping the bleeding of bones. Its original composition was 7 parts of bees wax, 1 part of almond oil, and 1 part of almond oil, and 1 part of salicyclic acid. The bone wax most frequently used today consists of 89 parts of bees wax and 11 parts of isopropyl palmitate. This preparation causes strong foreign-substance reactions and chronic inflammation reactions. A minor portion only is re-sorbed within 12 weeks, while at the same time the osteo-anagenesis is delayed considerably. From the clinical point of view, the possible formation of pseudo arthroses must be watched.
.
It is the ob~ect of the invention to provide a paste for haemostasis and temporary bridging of defects in cases of bone trauma, which paste will safely stop bleeding of the traumatized bone and not impede the osteogenesis but rather act osteoinductively. The solution of the problem posed is on the surprising finding that a paste containing 8 prolamin and finely dis-persed tricalcium phosphate or hydroxyl apatite and a physiologically com-patible diluent provides optimum haemostasis of the traumatized bone and is an excellent means for the temporary bridging of defects.
In accordance with the present teachings, a paste is provided for haemo-stasis and temporary bridging of defects in cases of bone trauma character-ized in that it contains from 3 to 60% by weight of prolamin and from 5 to 20% of tricalcium phosphate or hydroxyl apatite in finely dispersed form and a physiologically compatible diluent.
The diluent used preferably is a mixture of an aliphatic alcohol having from 2 to 5 carbon atoms, particularly ethanol and water at a volumetric ratio of approximately 1:1 to 10:0.5.
Prolamins are the major protein constituents of cereal grains or meal.
Contrary to all other proteins they can be extracted from flour by the use of 80% alcohol, yet they are not soluble in anhydrous alcohol or water. The most important prolamins are zein, gliadin, and hordein.
Zein is preferred in accordance with the invention. The prolamin, preferably zein is used in ,_~
23L~713 the paste in a quantity of from about 3 to 60, preferably 5 to 45% by weight.
Contrary to all other proteins, the prolamins are soluble in diluted alcohols and other solvents, but are not soluble in water. A mixture of ethanol and water is the preferred solvent and diluent, the water content ranging between 4 and 50%, depend-ing on how quickly the prolamin is desired to precipitate. In ethanol prolamins yield viscous, slightly thixotropic solutions.
The viscosity of the solutions rises as the concentration of ethanol rises, at the same prolamin content. On the other hand, the viscosity increases as the concPntration of prolamin in-creases, at a given concentration of ethanol.
The prolamins are resorbable so pseudoarthrosis cannot develop which is conceivable as a consequence of bone wax not being re-sorbed or being resorbed too slowly, e.g. in case of sternum closure.
The contents of finely dispersed hydroxyl apatite or tricalcium phosphate promote the regeneration of the bone. The particle size of the hydroxyl apatite or tricalcium phosphate in general lies within a range of from approximately 3 to 20 ~m, particu-larly from approximately 10 to 15 ~m.
The addition of methyl cellulose or carboxymethyl cell~lose in an amount of from 2 to 10% by weight provides optimum consisten-cy of the paste, thus yielding a preparation to stop bleeding of the bone when applied easily as a thin film. Also greater bone defects ca~ be filled and bridged by applying the paste.
Furthermore, it is possible to repair comminuted fractures.
An antibiotic may be added to the paste for use in prophylaxis and therapy of infections. Specific examples of useful anti-biotics are tobramycin, gentamycin, cefotaxim, and mixtures thereof. The antibiotic is used in suffici~ntly great quantity to obtain the complete inhibition of growth of the germs to be killed.
Instead of or in addition to the antibiotic the paste may con-tain a cytostatic drug. Specific examples of cytostatic sub-stances are mitomycin, dichlorene, decarbacin, or cisplatin.
~2~ 3 The cytostatic drug is used in an amount sufficient to retard the growth of the tumor.
Upon addition of fine fibers of resorbable polymer in an amount of from 1 to 15% by weight the consistency is changed such that the mass becomes kneadable and moldable so that it may be applied as a temporary bridging means of defects on bones~
Poly-~lactide-co-glycolide) is an hydrolyzable aliphatic poly-ester used to produce resorbable surgical suture material. Other resorbable fibrous polymers which may be incorporated in the paste according to the invention are polyglycolide, polylactide, polyoxalate, polysuccinate, polydioxanone, and poly-(esteramides).
The paste may be prepared in a way as disclosed in US patent 4,268,495 from which injectable solutions containing prolamin are known for embolization and occlusion.
It is easy to press the kneadable paste into bone defects and mold it so as to adapt it to the desired shape The mass solidi-fies within a period of from about 30 to 90 minutes.
The paste may be sterilized by gamma radiation, heat, or the addition of propylene oxide in an amount of from about 0.25 to 0.5% by weight.
The examples will explain the invention.
Example 1 A paste is prepared from the following components:
ethanol 60% V/V 51.7 g zein 19.4 g methyl cellulose 5.0 g tricalcium phosphate (particle size about 10~m~ 15.0 g propylene oxide 1.0 g The zein is introduced into the 60% aqueous ethanol, while care-fully stirring the mass. Upon complete dissolution (about 12 to 14 hours) pH adjustment is made to approximately 6.5 to 6.8, with the aid of a physiologically compatible acid or base . The ethyl cellulose and tricalcium phosphate then are introduced into the viscous solution obtained. The resulting paste finally is mixed in the cold with 1 g of propylene oxide and immediately bottled. An additional 1 to 13 g of fine fibers of a resorbable polymer, preferably polyglycolide or polylactide may be incorporated in the paste.
Example 2 In accordance with example 1 a paste is prepared from the com-ponents below:
ethanol 60% V~V 51.7 g zein 19.4 g carboxymethyl cellulose - 5.0 g hydroxyl apatite (particle size about 10 ~m) 20.0 g propylene oxide 1.0 g Upon longitudinal separation of the sternum of a dop the paste prepared in accordance with examples 1 and 2 is applied on the spongy part of the bone to stop the bleeding. The paste is applicable well and smoothly penetrates into the tiny cavities of the bone. Diffuse bleeding out of the bone is stopped at once.
Upon obduction after 28 days the partial bridging of the former defect can be observed. Histological proof of the haemostatic substance is no longer possible.
Example 3 In accordance with example l a paste is prepared from the components listed below:
ethanol 60% V/V 51.7 g zein 19.4 g methyl cellulose 5.0 g tricalcium phosphate (particle size about 10 ~m) 15.0 g tobramycin 0.7 g propylene oxide 1.0 g The paste according to the invention is used to fill an infect-ed bone cavity. Bone cavities in the ehronically infected bone marrow are a locus minoris resistentiae for recurring infections.
12~7~3 Upon cleaning of the bone marrow space up to sound tissue the paste is used to stop the bleeding which begins. At the same time the cavity either is filled completely or lined along the walls, depending on ~he size. The precipitation which initiates at once stops the paste from flowing out.
In a bacteriological test the bone pieces withdrawn periodically in the experiment demonstrated distinct inhibition of germ growth heyond the 28th day, and then at a declining tendency.
Example 4 In accordance with example 1 a paste is prepared from the fol-lowing components:
ethanol 60~ V/V 51.7 g zein 19O4 g carboxymethyl cellulose 5.0 g hydroxyl apatite (particle size about 10 ~m) 20.0 g mitomycin 0.8 g propylene oxide 1.0 g The paste according to the invention is used to retard the growth of malignant tumoxs of the bone or bone marrow which certainly or perhaps are existing. In context with the cytostatic drug mitomycin the paste either may be applied in a flowable consi-stency or in the form of the finest solid particles upon preci-pitation or evaporation of the solvent.
The flowable form wil~ be chosen if it is desired that the paste stop heavy bleeding from the area of tumor. Again a bone tumor may be treated which either is known and considered inoperable or which has been operated on and requires measures to stop the bleeding. The prophylactic introduction of a cytostatic drug to the border of the excision is of great advantage because in this way it can be guaranteed that the effectiveness of the cy-tostatic substance will last long enough. The range of the ef-fectiveness is to be assumed to reach about 1 cm away from the paste. As a systemic effect here is given under certain condi-tions only, the release of the cytostatic drug may be very high.
In fact it still amounts to several gamma up to a distance of
Claims (5)
1. A paste for haemostasis and temporary bridging of defects in cases of bone trauma, characterized in that it contains from 3 to 60% by weight of prolamin and from 5 to 20% of tricalcium phosphate or hydroxyl apatite in finely dispersed form and a physiologically compatible diluent.
2. The paste as claimed in claim 1, characterized in that the prolamin is aein and the diluent is a mixture of an aliphatic alcohol having from 2 to 5 carbon atoms and water.
3. The paste as claimed in claim 2, characterized in that the paste contains from 2 to 10% of methyl cellulose or carboxy methyl cellulose.
4. The paste as claimed in claims 1 to 3, characterized in that the paste in addition contains an antibiotic or a cytostatic agent.
5. The paste as claimed in one of claims 1 to 3, characterized in that it contains fine fibers of a resorbable polymer, preferably polyglycolide, polylactide, poly-(lactide-co-glycolide), polyoxalate, polysuccinate, polydioxanone, or poly-(esteramides).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP83101023.6 | 1983-02-03 | ||
| EP83101023A EP0115549B1 (en) | 1983-02-03 | 1983-02-03 | Paste for hemostasis and for temporary relief of defects in the traumatism of bones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1211713A true CA1211713A (en) | 1986-09-23 |
Family
ID=8190275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000446593A Expired CA1211713A (en) | 1983-02-03 | 1984-02-02 | Paste for haemostasis and temporary bridging of defects in cases of bone trauma |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0115549B1 (en) |
| JP (1) | JPS59148724A (en) |
| AT (1) | ATE31025T1 (en) |
| AU (1) | AU561584B2 (en) |
| CA (1) | CA1211713A (en) |
| DE (1) | DE3374659D1 (en) |
| ES (1) | ES8507349A1 (en) |
| IN (1) | IN158149B (en) |
| ZA (1) | ZA84805B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8402534A (en) * | 1984-08-17 | 1986-03-17 | Gerrit Johannes Brinks | MATERIAL, SUITABLE FOR USE AS AN IMPLANT MATERIAL IN HUMANS AND ANIMAL TO REPLACE ABSENT BONE TISSUE, AND METHOD FOR PREPARING THE MATERIAL. |
| JPH0755235B2 (en) * | 1986-09-08 | 1995-06-14 | 新田ゼラチン株式会社 | Injection material for bone formation |
| DE3825211A1 (en) * | 1988-07-25 | 1990-02-01 | Henkel Kgaa | IMPROVED BODY RESORBONABLE WAXES (III) |
| FR2668367B1 (en) * | 1990-10-26 | 1994-05-13 | Centre Nal Recherc Scientifique | IMPLANTABLE MEDICINE WITH PROLONGED EFFECT. |
| FR2715853B1 (en) * | 1994-02-08 | 1996-04-26 | Centre Nat Rech Scient | Composition for bio-material; preparation process. |
| GB2316940A (en) | 1996-08-30 | 1998-03-11 | Queen Mary & Westfield College | Silicon-substituted hydroxyapatite |
| JP3114016B2 (en) * | 1998-05-15 | 2000-12-04 | 株式会社ホギメディカル | Wound hemostatic material having cell adhesion promoting effect |
| GB2466979A (en) * | 2009-01-19 | 2010-07-21 | Simon James Baker | Porous ceramic compositions for use as haemostatic agents |
| DE102015014581A1 (en) | 2015-11-12 | 2017-05-18 | Nele Schmidt | Prolamine-containing gels, process for their preparation and their use |
| JP7372976B2 (en) * | 2019-01-08 | 2023-11-01 | 上海交通大学 | 3D printer ink, 3D printer ink manufacturing method, and gel |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2364644B1 (en) * | 1976-09-20 | 1981-02-06 | Inst Nat Sante Rech Med | NEW BONE PROSTHESIS MATERIAL AND ITS APPLICATION |
| DE2657370C2 (en) * | 1976-12-17 | 1982-11-11 | Hans Dr.med. Dr.med.dent. 8000 München Scheicher | Means for covering and / or filling in bone defects |
| GB1584080A (en) * | 1977-12-05 | 1981-02-04 | Ethicon Inc | Absorbable hemostatic composition |
| DE2843963A1 (en) * | 1978-10-09 | 1980-04-24 | Merck Patent Gmbh | BODY-RESORBABLE SHAPED MATERIAL BASED ON COLLAGEN AND THEIR USE IN MEDICINE |
| DE2803869C2 (en) * | 1978-01-30 | 1983-12-29 | Ethicon, Inc., 08876 Somerville, N.J. | Injectable embolization and occlusion solution |
| US4268495A (en) * | 1979-01-08 | 1981-05-19 | Ethicon, Inc. | Injectable embolization and occlusion solution |
| DE2917037C2 (en) * | 1979-04-27 | 1980-12-11 | Josef Dipl.-Chem. Dr. 8000 Muenchen Gaensheimer | Parenterally medicinal, partially absorbable multi-component material based on polymeric substances |
-
1983
- 1983-02-03 EP EP83101023A patent/EP0115549B1/en not_active Expired
- 1983-02-03 AT AT83101023T patent/ATE31025T1/en not_active IP Right Cessation
- 1983-02-03 DE DE8383101023T patent/DE3374659D1/en not_active Expired
-
1984
- 1984-01-24 IN IN49/CAL/84A patent/IN158149B/en unknown
- 1984-02-02 JP JP59016185A patent/JPS59148724A/en active Granted
- 1984-02-02 CA CA000446593A patent/CA1211713A/en not_active Expired
- 1984-02-02 ES ES529425A patent/ES8507349A1/en not_active Expired
- 1984-02-02 ZA ZA84805A patent/ZA84805B/en unknown
- 1984-02-02 AU AU24025/84A patent/AU561584B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES529425A0 (en) | 1985-09-01 |
| AU561584B2 (en) | 1987-05-14 |
| EP0115549B1 (en) | 1987-11-25 |
| JPH0359702B2 (en) | 1991-09-11 |
| ATE31025T1 (en) | 1987-12-15 |
| EP0115549A1 (en) | 1984-08-15 |
| ZA84805B (en) | 1985-09-25 |
| DE3374659D1 (en) | 1988-01-07 |
| AU2402584A (en) | 1984-08-09 |
| ES8507349A1 (en) | 1985-09-01 |
| JPS59148724A (en) | 1984-08-25 |
| IN158149B (en) | 1986-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6299905B1 (en) | Bioerodable polymeric adhesives for tissue repair | |
| CA2580948C (en) | Multi-purpose bio-material composition | |
| US5433751A (en) | Bone prosthesis material containing calcium carbonate particles dispersed in a bioresorbable polymer matrix | |
| Tamimi et al. | Brushite–collagen composites for bone regeneration | |
| EP2109444B1 (en) | Bone growth particles and osteoinductive composition thereof | |
| CA1211713A (en) | Paste for haemostasis and temporary bridging of defects in cases of bone trauma | |
| SK282122B6 (en) | Method for preparation of tissue implanting composition, tissue implant, intestinal submucosa and protease solubilised intestinal submucosa | |
| IE59059B1 (en) | Implantable medicament depot with gyrase inhibitor | |
| GB2032777A (en) | Bioresorbable masses containing collagen | |
| CA2264647A1 (en) | Fragmented polymeric hydrogels for adhesion prevention and their preparation | |
| JP2002501786A (en) | Irradiated and heat treated bone paste | |
| WO2008016983A2 (en) | Rapidly acting dry sealant and methods for use and manufacture | |
| JP6494285B2 (en) | Denatured collagen | |
| US20060257448A1 (en) | Resorbable polymer composition, implant and method of making implant | |
| US20080119859A1 (en) | Multi-Purpose Bio-Material Composition | |
| US4698326A (en) | Composition and method for osseous repair | |
| Flautre et al. | Influence of polymeric additives on the biological properties of brushite cements: an experimental study in rabbit | |
| US7820191B2 (en) | Calcium phosphate cements prepared from silicate solutions | |
| AU2012204139B2 (en) | Bone growth particles and osteoinductive composition thereof | |
| SK329592A3 (en) | Method of preparation of bioactive material | |
| Sazanova et al. | DO3. RAT BLOOD BIOCHEMICAL MARKERS TESTED AFTER CALVARIA IMPLANTATION WITH ION-MODIFIED CALCIUM PHOSPHATE BIOMATERIALS | |
| Ferrari Parabita et al. | New Methods of Fibrin Sealant (Tissucol/Tisseel) Application in Maxillofacial Surgery: The Use of Hydroxyapatite in Association with Human Fibrin Glue in Reconstructive Surgery | |
| Matras et al. | Selective Indications of Fibrin Sealing in Maxillofacial Surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |